Shire got hold of the eyedrop product in 2013 through its acquisition of SARcode which cost $160m and despite struggling on the market, Novartis is paying $3.4bn upfront to buy Xiidra.
It was no surprise that Takeda Pharmaceutical Co. Ltd. was looking to divest Xiidra, which it got access to following the $62bn acquisition of Shire PLC earlier this year, but the amount that Novartis AG has agreed to pay for the dry eye drug has certainly raised eyebrows.
The Swiss giant is to pay $3.4bn upfront for Xiidra (lifitegrast) plus potential milestone payments of up to $1.9bn, a...
While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.
